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Abstract
Background: The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treat-
ed with bisphosphonates and other antiresorptive agents is subject to controversy. The American Association of 
Oral and Maxillofacial Surgeons (AAOMS) has developed guidelines for the correct management of the disorder 
which are revised and updated by a panel of experts. 
Material and Methods: The present systematic review analyzes the different treatments currently used to treat 
this clinical condition, based on the PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement published in 2009. An electronic Medline search was made of the PubMed database, covering 
the period 2006-2014. The last search date was 31 December 2014. 
Results: A total of 29 articles were selected from the initial search according to the different drugs implicated 
in the appearance of osteonecrosis; the treatment modality used according to the stage of the disease; and the 
recorded success rate. 
Conclusions: It is currently still recommended that the management of MRONJ should be decided according to 
the stage of the disease – conservative treatment being preferred in early stages without symptoms, while surgical 
management is preferred in the case of bone exposure with symptoms.
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Introduction
The American Association of Oral and Maxillofacial 
Surgeons (AAOMS) has recently suggested changing 
the term “bisphosphonate-related osteonecrosis of the 
jaw (BRONJ)” to “medication-related osteonecrosis of 
the jaw (MRONJ)”, in view of the increase in frequency 
of maxillary and mandibular osteonecrosis related not 
only to bisphosphonates (BPs) but also to other antire-
sorptive agents such as denosumab and antiangiogenic 
drugs (1). The AAOMS position document has also 
modified the definition of MRONJ established in 2009 
(2), and patients susceptible to MRONJ are now defined 
as those presenting the following characteristics: a) a 
history of antiresorptive or antiangiogenic drug treat-
ment; b) the presence of bone exposure or intra- or ex-
traoral fistulization for over 8 weeks without remission; 
and c) no history of radiotherapy or diseases metastasiz-
ing to the maxilla.    
However, osteonecrosis of the jaw associated to these 
drugs has been the subject of controversy ever since 
the first case was reported in 2003 (3). The AAOMS 
considers prevention to be the key element in dealing 
with MRONJ. In this regard, a multidisciplinary team 
in which the dentist plays a fundamental role is required 
to define management of the lesions. Consultation of the 
dentist before starting antiresorptive or antiangiogenic 
drug treatment considerably reduces the risk of devel-
oping MRONJ in the event of osteonecrosis-triggering 
interventions such as tooth extractions (4-6).
Many authors have studied the management of MRONJ, 
including different treatments such as surgical debride-
ment, resection of the lesions, oxygen therapy and re-
cently also the use of mesenchymal cells to regenerate 
the damaged bone (7-9). The type of treatment depends 
on the diagnosis and clinical stage of MRONJ. A stag-
ing system was developed in 2006 by Ruggiero et al. 
(10), and was subsequently adopted by the AAOMS 
with updates in 2007, 2009 and 2014 (1,2,11).
Independently of the stage of the disease, initial treat-
ment must seek to control the pain and bone infection / 
necrosis, in order to preserve patient quality of life (1). 
Despite the current recommendations of the AAOMS 
advocating conservative management of MRONJ, a 
number of studies have found this approach to be suc-
cessful in only 20% of the cases, versus in over 85% 
when surgical treatment is decided (12).
The present study offers a systematic review of the 
different treatments currently used in application to 
MRONJ reflected in the literature, based on the stage of 
the disease, and examines the results of each treatment 
modality according to the associated success rates.
Material and Methods
The present systematic review was based on the PRIS-
MA® (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) statement published in 2009 
(13). An electronic Medline search was made of the 
PubMed database, covering the period 2006-2014. The 
last search date was 31 December 2014. The identified 
references were processed using Endnote®. 
Framing the question (PICO): What are the treatments 
used for medication-related osteonecrosis of the jaw and 
their success rates?
- Search strategy:
The literature search was made using the following 
key words: “medication”, “bisphosphonates”, “antire-
sorptive”, “antiangiogenic”, “denosumab”, “sunitinib”, 
“osteonecrosis”, “jaw” and “treatment”, combined with 
the boolean operators AND / OR. The electronic search 
was complemented by a manual search of the references 
found in the manuscripts and involving the following 
journals: British Journal of Oral and Maxillofacial Sur-
gery, International Journal of Oral and Maxillofacial 
Surgery, Journal of Oral and Maxillofacial Surgery, 
Oral Oncology, Oral Surgery, Oral Medicine, Oral Pa-
thology, Oral Radiology and Endodontology, Journal 
of Periodontology, Medicina Oral, Patología Oral y 
Cirugía Bucal. After eliminating duplications, the po-
tential titles and abstracts were filtered based on the fol-
lowing criteria:
- Inclusion criteria:
Articles entirely in English, referred to medication-re-
lated osteonecrosis of the jaw (bisphosphonates, antire-
sorptive agents and antiangiogenic drugs) in humans, 
and without sample limitations.
- Exclusion criteria:
Publications in languages other than English, system-
atic reviews, experimental studies in animals, and let-
ters to the Editor.
All the information was compiled from the selected 
articles by a single reviewer (FJRL). The document-
ed variables included general data such as the author, 
country, year of publication, objectives, patient charac-
teristics, and information referred to interventions and 
follow-up. The specific study variables included clini-
cal response indicators such as disappearance of the 
lesions, recurrence or evolution of the disease, and the 
frequency and severity of adverse reactions for the as-
sessment of safety.
Results and Discussion
The systematic PubMed search adopting the search 
strategy: (medication) AND osteonecrosis) AND jaw) 
AND treatment) AND (“2006/01/01” [Date - Publica-
tion] : “2014/12/31” [Date - Publication]) yielded a total 
of 85 articles. After reading the title and abstract, 74 of 
the articles that failed to meet the inclusion criteria were 
excluded from the study. The search strategy: (bispho-
sphonates) AND osteonecrosis) AND treatment) AND 
(“2006/01/01” [Date - Publication]: “2014/12/31” [Date 
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- Publication]) AND jaw yielded 1151 articles, of which 
15 meeting the inclusion criteria were included in the 
study. Lastly, the search strategy: (denosumab) AND 
osteonecrosis) AND treatment) AND (“2006/01/01” 
[Date-Publication]: “2014/12/31” [Date-Publication]) 
AND jaw yielded 74 articles, of which three meeting 
the inclusion criteria were included in the study. 
Following the electronic search and selection of the pub-
lications that met the established inclusion criteria, a to-
tal of 29 articles were selected (Fig. 1). A brief descrip-
tion of these studies is provided below, together with 
a summary of the different treatment options currently 
used in application to medication-related osteonecrosis 
of the jaw (MRONJ).
a) Conservative management
Patients amenable to conservative management would 
be those considered to be at risk and/or individuals 
without symptoms (stage I) (1). We could also include 
patients who for health reasons are not candidates for 
surgical treatment, or who are receiving cancer treat-
ment. Due to the intrinsic definition of MRONJ, which 
implies “exposed bone”, surgery in principle would be 
the treatment option of choice - though some authors 
consider that conservative management can improve 
or keep the disease asymptomatic in up to 70% of the 
cases. Nevertheless, this favorable percentage cannot 
be regarded as representing treatment success, though 
temporary patient relief is provided (14). Conservative 
management includes the reinforcement of oral hygiene, 
periodic dental checks, oral rinses with chlorhexidine, 
and antibiotic treatment. In this regard, the most widely 
used antibiotics are amoxicillin with or without clavu-
lanic acid (500 mg/1 g) clindamycin (300 mg), azithro-
mycin (500 mg) and in some cases the combination of 
metronidazole with betalactams. In most of the studies, 
this approach resulted in the stabilization of osteone-
crosis or simply the improvement of symptoms (14,15). 
In fact, higher success rates are only achieved when 
such treatments are combined with other conservative 
measures such as ozone therapy, hyperbaric oxygen and 
low-power laser therapy - though the rates are not com-
parable to those obtained with surgery (16).
Ozone therapy stimulates cell proliferation and soft tis-
sue healing, and reduces pain, with promising results in 
phase I/II clinical trials. As such, this treatment modali-
ty could constitute a new alternative in the management 
of MRONJ (17). Hyperbaric oxygen (HBO) has some-
times been used in application to MRONJ, with contro-
versial results. Historically, the healing action of HBO 
has been attributed to the creation of beneficial oxygen 
Fig. 1. PRISMA® flowchart describing the search strategy and inclusion of the studied articles.
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gradients. The reason for using HBO in MRONJ is that 
different authors consider it to improve wound healing, 
reduce edema and swelling, stimulate stem cell mobi-
lization, and moderate the bone turnover suppression 
caused by bisphosphonates (16,18). Low-intensity laser 
therapy (LILT) has been shown to be an innovating and 
effective treatment in medicine, with effects that include 
the lessening of pain, improved wound healing, and the 
facilitation of nerve regeneration. It also exerts antimi-
crobial effects and facilitates the healing of wounds in 
the oral cavity, including the stimulation of reepitheliza-
tion after periodontal or third molar surgery. Different 
studies have warranted the use of LILT on the basis of 
its biostimulating effects in MRONJ lesions (16,19).
Pentoxifylline and α-tocopherol have been suggested 
to assist antimicrobial therapy in the early stages of 
MRONJ, since these substances have been found to re-
duce the bone exposure area and symptoms in 74% of 
the cases (16,20). Table 1 summarizes the studies made 
using conservative treatments in MRONJ, with the as-
sociated success rates (21-23).
a) Surgical management, alone or in combination with 
other treatments
There is general agreement on the advisability of sur-
gery in those cases characterized by chronic exposure 
of necrotic bone, since the latter can interfere with 
wound healing and is of course infected (24). In these 
cases, minimum necessary necrotic bone elimination 
is indicated, and two surgical approaches have been 
recommended in this respect: (i) conservative debride-
ment or surgery; and (ii) segmental resection. This lat-
ter approach applies to stage II/III MRONJ and cases in 
which nonsurgical conservative management has failed 
(24) (Table 2).
i.) Conservative surgery
Conservative surgery involves the removal of dead bone 
TYPE OF TREATMENT AUTHOR / YEAR
No. PATIENTS HEALED / No. 
PATIENTS TREATED (%)
Antibiotic treatment
Melea et al. (2014) (15)
Van den Wyngaert et al. (2009) (21)
Scoletta et al. (2010) (22)
Nicolatou-Galitis et al. (2011) (23)
23/38 (60%)
16/33 (53%)
18/30 (62%)
7/47 (14.9%)
T Antibiotic treatment + hyperbaric oxygen Freiberger et al. (2012) (18) 13/25 (52%)
Antibiotic treatment + ozone therapy Ripamonti et al. (2011) (17) 10/10  (100%)
Pentoxifylline + α-tocopherol Magremanne et al.  (2014) (20) 1/1 (100%)
TYPE OF TREATMENT AUTHOR / YEAR No. PATIENTS HEALED / No. PATIENTS TREATED (%)
CONSERVATIVE SURGERY
Rugani et al. 2014 (24)
Vescovi et al. (2012) (28)
Thumbigere-Math et al. (2009) (30)
Williamson et al. (2010) et al. (25)
Vescovi et al. (2014) (16)
Graziani et al. (2012) (26)
Wutzl et al. (2008) (27)
15/17 (88.2%)
11/17 (65%)
3/19 (15%)
40/40 (100%)
25/27 (92.6%)
227 (54%)
24/41 (59%)
CONSERVATIVE SURGERY 
+ OZONE THERAPY Agrillo et al. (35) 57/94 (60%)
CONSERVATIVE SURGERY 
+ L-PRF Kim et al. (41) 26/34 (77%)
RESECTIVE SURGERY 
Graziani et al. (2012) (26) 
Carlson and Basile (2009) (34)
Bedogni et al. (2011) (31)
Voss et al. (2012) (32)
Schubert et al. (2012) (33)
87/120 (72.5%)
87/95 (92%)
27/30 (90%)
20/21 (95%)
47/54 (87%)
Table 1. Summary of studies involving a conservative approach to the management of medication-related osteonecrosis of the jaw. 
(MRONJ).
Table 2. Summary of studies involving a surgical approach to the management of medication-related osteonecrosis of the jaw 
(MRONJ). L-PRF (Leukocyte- and platelet-rich fibrin mesh).
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(sequestrectomy) and/or superficial surgical debride-
ment of necrotic bone associated to oral antibiotics and 
chlorhexidine rinses. Most authors recommend scantly 
invasive surgery for MRONJ, since according to the re-
viewed literature this approach affords healing rates of 
over 50% (16,25-27). Wutzl et al. (27) carried out the 
first prospective study evaluating the outcome of sur-
gery after 6 months in a cohort of 58 patients with os-
teonecrosis of the jaw. They found 58.5% of the patients 
to be free of pain and with an intact oral mucosa. Eleven 
out of 12 patients subjected to flap procedures for soft 
tissue closure presented a healthy mucosa. The authors 
showed that minimal resection of the necrotic bone and 
local soft tissue closure can afford satisfactory results.
Complementary treatments added to surgery have also 
been described in the literature. Vescovi et al. (28) ob-
tained good results in MRONJ by combining surgical 
debridement with laser therapy. However, Atalay et al. 
(19) observed no statistically significant benefits with 
this approach compared with conventional surgery. 
Martins et al. (29) conducted a study in patients treated 
with antibiotics plus surgery, followed by low-intensity 
laser therapy and platelet-rich plasma applied to the sur-
gical wound. The healing rates were found to be higher 
than in the patients subjected only to surgery and anti-
biotic treatment. In contrast, other investigators such as 
Thumbigere-Math et al. recorded a success rate of only 
15% and observed colonization by Actinomyces spp. in 
those cases with exposed bone (30).
ii) Resective or extensive (segmental) surgery
In those patients in which previous treatment has failed, 
or in very advanced cases of MRONJ, resective or ex-
tensive (segmental) surgery is indicated with the pur-
pose of eliminating all the necrotic tissue, leaving only 
healthy bone. However, resective surgery has generated 
controversy, since in many cases it is difficult to elimi-
nate all the necrotic bone and guarantee the obtainment 
of healthy bone margins (31-33). Carlson and Basile 
(34) reported a very high success rate (92%) in MRONJ 
patients subjected to mandibular segmental resection 
and partial maxillectomy with the purpose of securing 
clean margins with healthy bone. However, disinfec-
tion measures associated to the surgical procedure are 
needed - hence the combination of surgery with other 
therapies such as ozone (35), laser irradiation (16) and, 
in particular, prolonged antibiotic treatment (generally 
penicillin, or tetracycline or clindamycin in patients al-
lergic to penicillin) (36). Additional measures such as 
the use of stem cells (9,37), platelet-rich plasma (38), 
the administration of parathyroid hormone (39,40), or 
the use of leukocyte and platelet-rich fibrin meshes (41) 
are also promising strategies - though further clinical 
studies are needed in order to confirm their efficacy / 
effectiveness.
Conclusions
It is currently still recommended that the management 
of MRONJ should be decided according to the stage of 
the disease – conservative treatment being preferred in 
early stages without symptoms, while surgical man-
agement is preferred in the case of bone exposure with 
symptoms. Effective and scantly invasive alternatives 
affording good patient quality of life will be the future 
treatments of choice, though at present there is no agree-
ment as to which management approach is best suited to 
each specific circumstance.
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